This article is more than 5 years old. Information may no longer be current.

CATT completes enrollment; first results expected in early 2011

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

KOLOA, Hawaii — The first major clinical trial to compare bevacizumab and ranibizumab in a head-to-head fashion has completed enrollment, and the first data analysis is expected in about 1 year.

Daniel F. Martin

Although the head-to-head comparison of Avastin (bevacizumab, Genentech) and Lucentis (ranibizumab, Genentech) in CATT (Comparisons of age-related macular degeneration treatments trials) has generated the most interest, other findings from the trial may ultimately prove more useful, Daniel F. Martin, MD, said at Retina 2010.

"The actual Lucentis vs. Avastin comparison is the one that has garnered the most attention in the press, and yet the aspect of CATT that I find most interesting is the comparison of fixed vs. variable dosing, and the hope that we can identify subgroups within the variable dosing that can predict how to better treat these patients," Dr. Martin said.

Results from CATT may eventually be compared with data from the IVAN trial, a separate but nearly identical trial currently being conducted in the United Kingdom. Unlike CATT, the IVAN trial requires three loading doses, as well as three serial monthly doses at any recurrence of fluid, Dr. Martin said.

The first results from CATT are expected in January 2011, Dr. Martin said. Four additional multicenter clinical trials are ongoing around the world evaluating bevacizumab and ranibizumab in a head-to-head comparison.

Hawaiian Eye and Retina 2011 will be held January 16-21, 2011 at the Hyatt Regency Maui Resort & Spa in Ka'anapali, Maui. Learn more at OSNHawaiianEye.com.